PhenoCode Signature Panels
Whether you are developing a predictive biomarker assay, understanding immunotherapy responses, developing the next-gen immunotherapy, or validating your biomarker studies, the PhenoCode™ Signature Panels provide you the flexibility to keep pace with the dynamic combination therapy landscape by characterizing the tumor microenvironment (TME).
Predictive spatial signatures for the next generation of combination therapies
The development of clinically useful biomarkers to select responders for combination therapies is critical for the advancement of such treatments.
A meta-analysis has shown that spatial phenotyping, enabled by multiplexed imaging, more accurately predicts patient response to anti-PD-1/PD-L1 therapy than other biomarker assay modalities. Spatial signatures are a novel biomarker class, developed by spatially phenotyping the TME, that can better predict immunotherapy response.
PhenoCode Signature – How it works
PhenoCode Signature Panels were designed to be complementary, enabling mapping of the tumor microenvironment while also providing flexibility to add biomarkers of interest to 5-plex base panels.
Learn about the assay workflow and key advantages these assays provide.
Develop spatial signature three times faster
PhenoCode Signature panels are optimized and validated to enable the rapid development of spatial signatures.
Bring your plus one.
Customize your own panel.
Each PhenoCode Signature Panel has five foundational biomarkers and is designed to integrate one additional biomarker of your choice—analyze additional cell phenotypes or address your specific research question.
Five-plex panel
Choose the PhenoCode Signature Panel from the following options:
- Immuno-Contexture Human Protein Panel
- Immune Profile Human Protein Panel
- Activated TIL Status Human Protein Panel
- T Cell Status Human Protein Panel
Choose an additional biomarker of your choice. You can:
- Select a validated biomarker from our list
- Use an antibody conjugation kit to barcode your antibody
Each PhenoCode Signature Panel addresses a fundamental question of the TME.
Tumors characterized as “hot” exhibit signs of inflammation with T-cell infiltration making them more likely to respond to single-agent and combination therapies.
The composition of immune cells within the TME varies between tumors and is strongly associated with outcomes of single-agent and combination therapies.
The ability to determine the tumor proliferative state and the activation status of the tumor-infiltrating lymphocytes (TILs) could provide important information to guide therapeutic decisions.
T-cell exhaustion and the presence of immunosuppressive cells can contribute to an immunosuppressive TME. Recognition of these states can direct therapeutic strategies aimed at overcoming immunotherapy resistance.
A scalable end-to-end solution
The development of spatial signatures requires a solution that easily integrates staining, imaging, and analysis using existing workflows while providing accuracy and reproducibility.
Stain
Whole-slide staining of tissues in a single step
Image
Patented multispectral imaging technology provides rapid, whole-slide image acquisition with walk-away automation
Analyze
Visualize and interpret data using the included software suite or an open-source solution
PhenoCode Signature Panels
Ask the right questions. The PhenoCode Signature Panels are carefully curated and designed with a selection of protein targets to enable comprehensive analysis of the tumor microenvironment.
PhenoCode Signature Immuno-Contexture Human Protein Panel
Including biomarkers CD8, CD68, PD-L1, FoxP3, and PanCK, this panel profiles the TME for CD8-positive T lymphocytes and PD-L1 expression.
PhenoCode Signature Immune Profile Human Protein Panel
The panel profiles the TME using four key immune cell markers (CD8, CD68, CD3e, and CD20) and a tumor marker (PanCK).
PhenoCode Signature Activated TIL Status Human Protein Panel
Including biomarkers CD8, CD3e, Ki67, Granzyme B, and PanCK, this panel determines Ki67 positivity in addition to profiling of the TME for activated CD8-positive T lymphocytes.
PhenoCode Signature T Cell Status Human Protein Panel
Including biomarkers CD8, CD4, CD20, FoxP3, and PD-1, this panel identifies distinct T-cell subsets and effector functionality status.
Get expert guidance to select the right PhenoCode Signature Panel
Not sure which PhenoCode Signature Panel fits your research needs? Our experts are here to help. Request a consultation to identify the optimal panel for your targets and therapeutic focus—so you can accelerate your spatial biology insights with confidence.